Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Deferred Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Current Deferred Revenue data on record, last reported at $7.6 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 876.23% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $7.6 million, up 876.23%, while the annual FY2024 figure was $7.6 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $7.6 million in Q3 2025 per SGMO's latest filing, roughly flat from $7.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $94.4 million in Q1 2021 and bottomed at $774000.0 in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $43.5 million, with a median of $30.7 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: tumbled 97.93% in 2023, then skyrocketed 876.23% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $85.7 million in 2021, then plummeted by 39.59% to $51.8 million in 2022, then tumbled by 97.13% to $1.5 million in 2023, then surged by 408.82% to $7.6 million in 2024, then changed by 0.0% to $7.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $7.6 million in Q3 2025, $7.6 million in Q2 2025, and $7.6 million in Q1 2025.